On October 3, Bitcoin's mining difficulty decreased by 0.03% to approximately 132.72 trillion, following a 4.16% increase in September. This adjustment occurred at block 969,696 and reflects a slight easing in mining competition. The network's estimated hashrate stands at 986.07 exahashes per second. Bitcoin adjusts mining difficulty every 2,016 blocks to maintain an average block time of about 10 minutes, ensuring network stability.
Bitcoin mining difficulty, noted for a slight 0.03% decrease after a prior 4.16% rise in September, is presented here alongside Pluang's cryptocurrency market snapshot. For readers following digital assets, as of Oct 04, 2026 00:21 WIB, 24 of 50 major cryptocurrencies on Pluang rose while 25 fell. Notable daily gainers include ONE (Harmony) up 20.60% at Rp47 with a typical hold time of 152 days, SAND (The Sandbox) up 12.53% at Rp1,309 with 123 days hold time, and BAL (Balancer) up 11.14% at Rp16,297 with 85 days hold time.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
